TABLE 4.
Pre- and postvaccination geometric mean serum bactericidal antibody titersa
| Laboratory and strain group | Strain | Subject group | Timing | n | GMT (95% CI) |
|---|---|---|---|---|---|
| GSK | |||||
| Vaccine homologous or PorA related strains | M97250687 | MenB 0-2-4m | Prevacc | 155 | 2.85 (2.27-3.57) |
| Postvacc | 153 | 10.94 (8.37-14.29) | |||
| MenB 0-1-6m | Prevacc | 151 | 2.68 (2.19-3.28) | ||
| Postvacc | 149 | 12.33 (9.45-16.08) | |||
| Control 0-1-6m | Prevacc | 76 | 2.44 (1.82-3.29) | ||
| Postvacc | 76 | 2.78 (2.05-3.77) | |||
| NZ124/98 | MenB 0-2-4m | Prevacc | 152 | 4.11 (3.20-5.28) | |
| Postvacc | 150 | 22.52 (18.41-27.56) | |||
| MenB 0-1-6m | Prevacc | 149 | 4.04 (3.16-5.16) | ||
| Postvacc | 149 | 25.01 (20.41-30.63) | |||
| Control 0-1-6m | Prevacc | 52 | 4.95 (3.48-7.04) | ||
| Postvacc | 53 | 4.16 (2.85-6.08) | |||
| Vaccine heterologous strains | B16B6 | MenB 0-2-4m | Prevacc | 154 | 1.38 (1.21-1.58) |
| Postvacc | 149 | 2.64 (2.11-3.31) | |||
| MenB 0-1-6m | Prevacc | 148 | 1.18 (1.10-1.27) | ||
| Postvac | 148 | 2.92 (2.34-3.65) | |||
| Prevacc | 52 | 1.73 (1.23-2.42) | |||
| Postvacc | 51 | 1.92 (1.34-2.75) | |||
| BZ10 | MenB 0-2-4m | Prevacc | 152 | 3.59 (2.75-4.68) | |
| Postvacc | 150 | 8.11 (6.03-10.90) | |||
| MenB 0-1-6m | Prevacc | 150 | 2.99 (2.35-3.81) | ||
| Postvacc | 148 | 9.60 (7.32-12.59) | |||
| Control 0-1-6m | Prevacc | 54 | 5.04 (3.09-8.22) | ||
| Postvacc | 54 | 5.37 (3.28-8.79) | |||
| H44/76 | MenB 0-2-4m | prevacc | 155 | 2.27 (1.85-2.78) | |
| Postvacc | 149 | 8.82 (6.41-12.14) | |||
| MenB 0-1-6m | Prevacc | 151 | 1.88 (1.57-2.24) | ||
| Postvacc | 149 | 6.64 (5.00-8.82) | |||
| Control 0-1-6m | Prevacc | 53 | 2.63 (1.70-4.08) | ||
| Postvacc | 53 | 2.14 (1.52-2.99) | |||
| HPA | |||||
| Vaccine homologous or PorA related strains | M02240149 | MenB 0-1-6m | Prevacc | 77 | 4.46 (3.58-5.55) |
| Postvacc | 76 | 23.47 (17.51-31.46) | |||
| Control 0-1-6m | Prevacc | 37 | 5.93 (3.81-9.21) | ||
| Postvacc | 38 | 5.66 (3.65-8.78) | |||
| M01240101 | MenB 0-1-6m | Prevacc | 74 | 16.61 (12.65-21.81) | |
| Postvacc | 75 | 34.46 (25.51-46.54) | |||
| Control 0-1-6m | Prevacc | 36 | 14.53 (9.06-23.32) | ||
| Postvacc | 35 | 18.75 (11.48-30.61) | |||
| Vaccine heterologous strains | M01240013 | MenB 0-1-6m | Prevacc | 76 | 7.78 (5.72-10.60) |
| Postvacc | 76 | 29.75 (22.55-39.24) | |||
| Control 0-1-6m | Prevacc | 37 | 8.95 (5.86-13.68) | ||
| Postvacc | 38 | 8.15 (5.61-11.8) | |||
| M01240355 | MenB 0-1-6m | Prevacc | 76 | 7.57 (5.58-10.28) | |
| Postvacc | 77 | 28.72 (19.93-41.40) | |||
| Control 0-1-6m | Prevacc | 37 | 8.31 (4.98-13.84) | ||
| Postvacc | 38 | 8.76 (5.64-13.62) | |||
| H44/76 | MenB 0-1-6m | Prevacc | 74 | 3.89 (2.93-5.16) | |
| Postvacc | 76 | 14.87 (10.27-21.55) | |||
| Control 0-1-6m | Prevacc | 36 | 3.92 (2.69-5.73) | ||
| Postvacc | 37 | 4.73 (3.07-7.31) | |||
| M01240185 | MenB 0-1-6m | Prevacc | 77 | 2.50 (2.19-2.87) | |
| Postvacc | 77 | 4.00 (3.21-4.99) | |||
| Control 0-1-6m | Prevacc | 37 | 3.02 (2.36-3.86) | ||
| Postvacc | 38 | 3.33 (2.36-4.71) |
a
See Table 1 for typing of strains. n, number of subjects with available results for specified assay. Prevacc, prevaccination blood sample at month 0; Postvacc, post-dose 3 vaccination blood sample at month 5 (MenB 0-2-4m) or month 7 (0-1-6m groups).